The physiology of glucagon-like peptide 1.

نویسنده

  • Jens Juul Holst
چکیده

Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. The current knowledge regarding regulation of proglucagon gene expression in the gut and in the brain and mechanisms responsible for the posttranslational processing are reviewed. GLP-1 is released in response to meal intake, and the stimuli and molecular mechanisms involved are discussed. GLP-1 is extremely rapidly metabolized and inactivated by the enzyme dipeptidyl peptidase IV even before the hormone has left the gut, raising the possibility that the actions of GLP-1 are transmitted via sensory neurons in the intestine and the liver expressing the GLP-1 receptor. Because of this, it is important to distinguish between measurements of the intact hormone (responsible for endocrine actions) or the sum of the intact hormone and its metabolites, reflecting the total L-cell secretion and therefore also the possible neural actions. The main actions of GLP-1 are to stimulate insulin secretion (i.e., to act as an incretin hormone) and to inhibit glucagon secretion, thereby contributing to limit postprandial glucose excursions. It also inhibits gastrointestinal motility and secretion and thus acts as an enterogastrone and part of the "ileal brake" mechanism. GLP-1 also appears to be a physiological regulator of appetite and food intake. Because of these actions, GLP-1 or GLP-1 receptor agonists are currently being evaluated for the therapy of type 2 diabetes. Decreased secretion of GLP-1 may contribute to the development of obesity, and exaggerated secretion may be responsible for postprandial reactive hypoglycemia.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Serum Glucagon-Like Peptide-1 Changes in Women with Type 2 Diabetes Following a Four Weeks Aerobic Exercise

Objective: The objective of this study was to investigate the effect of four weeks aerobic training on serum glucagon-like peptide-1 (GLP-1) in women with type 2 diabetes mellitus (T2DM). Materials and Methods: Twenty T2DM patients (33-53 years) were randomly assigned into control (n=10) and experimental (n=10) groups. The main intervention included running on treadmill, reaching 55 to 80% o...

متن کامل

EFFECTS OF AEROBIC TRAINING ON DIPEPTIDYL PEPTIDASE-4 AND GLUCAGON-LIKE PEPTIDE-1 IN OBESE WOMEN WITH TYPE 2 DIABETES

Background: Obesity increases the risk of developing type 2 diabetes with regard to the hormones involved. The purpose of this quasi-experimental study was to investigate the effect of aerobic exercise on Dpp-4 and GLP-1 in obese women with type 2 diabetes. Methods: From among obese women with type-2 diabetes mellitus 35-50 years old referred to the Diabetes Association of Saveh, 20 people wer...

متن کامل

Effects of Fasting on Glucagon-like peptide-1 hormone (GLP-1), and Lipid Profile Indices in Obese and Thin Women

Introduction: Glucagon-like peptide-1 hormone (GLP-1) contributes to the regulation of insulin and glucose concentration. However, the effects of fasting on GLP-1 response in different people has not been determined yet. The aim of the present research was to investigate the effect of fasting on GLP-1 and the lipid profile of obese and thin women.Materials and methods: In this research, 25 obes...

متن کامل

Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide.

Many peptides are synthesized and released from the gastrointestinal tract and pancreas, including pancreatic polypeptide (PP) and the products of the gastrointestinal L cells, glucagon-like peptide 1 (GLP-1), oxyntomodulin, and peptide YY (PYY). Whereas their roles in regulation of gastrointestinal function have been known for some time, it is now evident that they also influence eating behavi...

متن کامل

An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning

Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be...

متن کامل

Proglucagon-derived peptides: mechanisms of action and therapeutic potential.

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Physiological reviews

دوره 87 4  شماره 

صفحات  -

تاریخ انتشار 2007